ArticleFrontiers in bioengineering and biotechnology2025
Enhancing lateral flow immunoassay performance for cardiac troponin I detection with pore-size tailored silica nanoparticles and smartphone-based "AdaptiScan" analysis.
Article in Frontiers in bioengineering and biotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The accurate and rapid detection of cardiac troponin I (cTnI) at the point of care is crucial for the timely diagnosis of myocardial infarction (MI). This study introduces an advanced lateral flow immunoassay (LFIA) platform for cTnI detection. We employed small-sized, large-pore dendritic mesoporous silica nanoparticles (DMSN-2) to encapsulate quantum dots (QDs), achieving an enhanced QD loading capacity of 1.427 g QD/g silica, compared to 0.881 g QD/g silica for smaller pore counterparts (DMSN-1). This nano-LFIA was further integrated with "AdaptiScan", a smartphone-based detection system that uses adaptive detection algorithms to automatically extract and analyze fluorescence signals from LFIA strips. This integration of pore-size tailored DMSNs and "AdaptiScan" resulted in a limit of detection for cTnI of 42.6 ng/L, which meets clinical diagnostic requirements. The platform offers a sensitive, cost-effective, and portable solution for rapid detection of MI, potentially transforming point-of-care testing in resource-limited settings.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.